Boehringer Ingelheim reported that its dual-acting obesity drug survodutide succeeded in a phase 3 trial, producing significantly greater weight loss than placebo in a 76-week study. The company said trial results also suggested participants may reduce weight while preserving muscle mass, addressing a known concern seen with some obesity medications. Analysts are expected to scrutinize longer-term safety and additional efficacy details, including related liver outcomes in a MASH study. The results put another GLP-1-adjacent mechanism into the competitive obesity landscape beyond semaglutide and tirzepatide.